Normal Tension Glaucoma (NTG)Phase 2NightingaleNCT06030193
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
A Phase 2 study testing QLS-111 ophthalmic solution (0.015%) and Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) in people with Normal Tension Glaucoma (NTG) and Low-Tension Glaucoma, Bilateral, run by Qlaris Bio, Inc. at 1 site in South Korea.
Trial summary
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients. Read more about this study
- Who is it for?
- Ages 30 years and older
- Conditions the study is for
- Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye
- What is being tested?
- QLS-111 ophthalmic solution (0.015%) and Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 37 participants
- Where
- 1 siteSouth Korea
- Study dates
- 13 Aug 2025to 23 Mar 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 30 years or older
- Able to provide written acknowledgement of giving informed consent
- Best corrected visual acuity (BCVA) 20/200 or better
- NTG in both eyes with untreated IOP <21 mmHg at Visit 2 and morning assessment of Visit 3; IOP at morning assessment on Visits 2 and 3 doesn't differ more than 2 mmHg; has open iridocorneal angles, historic IOP <22 mmHg in either eye
Who cannot join
- History of angle closure glaucoma, narrow or occludable angle on gonioscope
- All secondary glaucomas
- Severe glaucomatous damage that would preclude safe washout of prescribed ocular hypotensive medications
- Previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes, cyclodestructive procedure) (selective laser trabeculoplasty (SLT) allowed if done no earlier than 1 year from study, some minimally invasive glaucoma surgeries are allowed if done no earlier than 1.5 years from study)
- Ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis of eye
- Use of other ophthalmic concomitant medications during the study
Show all 11Show fewer
- Refractive surgery
- Uncontrolled hypertension or hypotension
- Significant systemic or psychiatric disease
- Participation in other investigational trial 30 days prior to screening or previous enrollment and treatment with Qlaris investigational product
- Pregnant or lactating
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Active-controlled, Multi-site, Double-masked, Pilot Study to Evaluate the Safety and Tolerability of QLS-111 Versus Timolol Maleate Preservative Free 0.5% Ophthalmic Solution in Subjects With Normal Tension Glaucoma (NTG)
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.
Read the detailed description
A randomized, active-controlled, multi-site, double-masked, pilot study to evaluate the safety and tolerability of QLS-111 0.015% versus Timolol maleate ophthalmic preservative free (PF) 0.5% ophthalmic solution in subjects with NTG. Primary objective is to evaluate the ocular and systemic safety and tolerability of QLS-111 0.015% compared to active control (Timolol).
Secondary objective is to evaluate the ocular hypotensive efficacy of QLS-111 0.015% with once daily evening (QPM) and twice daily (BID) dosing versus Timolol with QPM dosing.
- Conditions
- Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye, Glaucoma
- Being tested
- QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)
- Keywords
- NTG, Qlaris, intraocular pressure (IOP), Glaucoma, Nightingale, low-tension glaucoma
- Medical subject headings
- Low Tension Glaucoma, Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QLS-111 ophthalmic solution (0.015%)Drug
Also called QLS-111
QLS-111 ophthalmic solution 0.015% applied QPM OU for 7 days followed by BID dosing OU for 7 days, to constitute a 14-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)Drug
Also called Timolol
Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) with BID dosing OU will be administered up to 14 days. All IP for this study will be supplied masked in PF single use vials.
| Study group | Role | What they receive |
|---|---|---|
| QLS-111 ophthalmic solution | Experimental | Qlaris' investigational product, QLS-111 ophthalmic solution, 0.15%, provided in single use vials, masked, and PF. Receives: Drug: QLS-111 ophthalmic solution (0.015%) |
| Timolol maleate PF 0.5% Ophthalmic Solution | Active comparator | Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) provided in single use vials, masked. Receives: Drug: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs)
Ocular safety and tolerability: (AEs)
Measured: 14 days
Clinically significant change in visual acuity
Ocular safety and tolerability: visual acuity
Measured: 14 days
Clinically significant change in findings on slit lamp exam
Ocular safety and tolerability: dilated biomicroscopy of eye to observe clinically significant changes from baseline
Measured: 14 days
Clinically significant change in findings on fundus exam
Ocular safety and tolerability: dilated ophthalmoscopy to observe clinically significant changes from baseline in posterior segment of eye
Measured: 14 days
Incidence of systemic TEAEs
Systemic safety and tolerability: AEs
Measured: 14 days
Clinically significant changes in blood pressure (BP)
Systemic safety and tolerability: vital sign, measuring systolic and diastolic blood pressure
Measured: 14 days
Clinically significant changes in heart rate (HR)
Systemic safety and tolerability: vital signs
Measured: 14 days
Secondary outcomes (2)
Change from baseline (CFB) of diurnal intraocular pressure (IOP) in the study eye
Ocular hypotensive efficacy: diurnal IOP CFB
Measured: 14 days
CFB in IOP at various timepoints in the study eye
Ocular hypotensive efficacy: IOP CFB for multiple timepoints throughout the day
Measured: 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2023
- Study start13 Aug 2025
- Primary completion23 Feb 2026
- Study completion23 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Normal Tension Glaucoma (NTG)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Multi site double masked, active-controlled, randomized, prospective parallel, pilot study of 7 days' QPM dosing, followed by 7 days' BID dosing (7 days of dosing per regimen \[14-day treatment period\]) of an investigational product (IP), QLS-111 or Timolol. Both eyes (OU) will be dosed.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 37 participants (actual)
Sponsor and investigators
- Lead sponsor
- Qlaris Bio, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Lisa Brandano, Study director, Qlaris Bio, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06030193
- Sponsor's protocol ID
- QC-111-202
- Other IDs
- Nightingale
- Acronym
- Nightingale
- Status last verified
- Mar 2026
- First submitted
- 18 Aug 2023
- Last updated
- 3 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Active-controlled, Multi-site, Double-masked, Pilot Study to Evaluate the Safety and Tolerability of QLS-111 Versus Timolol Maleate Preservative Free 0.5% Ophthalmic Solution in Subjects With Normal Tension Glaucoma (NTG)
- ClinicalTrials.gov ID
- NCT06030193
- Acronym / sponsor ID
- Nightingale / QC-111-202
- Conditions
- Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye, Glaucoma
- Keywords
- NTG, Qlaris, intraocular pressure (IOP), Glaucoma, Nightingale, low-tension glaucoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 37 participants (actual)
- Lead sponsor
- Qlaris Bio, Inc.Industry (pharma, biotech, devices)
- Study start
- 13 Aug 2025 (actual)
- Primary completion
- 23 Feb 2026 (actual)
- Study completion
- 23 Mar 2026 (actual)
- First posted
- 8 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.
Detailed description
A randomized, active-controlled, multi-site, double-masked, pilot study to evaluate the safety and tolerability of QLS-111 0.015% versus Timolol maleate ophthalmic preservative free (PF) 0.5% ophthalmic solution in subjects with NTG. Primary objective is to evaluate the ocular and systemic safety and tolerability of QLS-111 0.015% compared to active control (Timolol).
Secondary objective is to evaluate the ocular hypotensive efficacy of QLS-111 0.015% with once daily evening (QPM) and twice daily (BID) dosing versus Timolol with QPM dosing.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Multi site double masked, active-controlled, randomized, prospective parallel, pilot study of 7 days' QPM dosing, followed by 7 days' BID dosing (7 days of dosing per regimen [14-day treatment period]) of an investigational product (IP), QLS-111 or Timolol. Both eyes (OU) will be dosed.
| Arm | Type | Receives |
|---|---|---|
| QLS-111 ophthalmic solution | Experimental | Drug: QLS-111 ophthalmic solution (0.015%)Qlaris' investigational product, QLS-111 ophthalmic solution, 0.15%, provided in single use vials, masked, and PF. |
| Timolol maleate PF 0.5% Ophthalmic Solution | Active comparator | Drug: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) provided in single use vials, masked. |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- 30 years or older
- Able to provide written acknowledgement of giving informed consent
- Best corrected visual acuity (BCVA) 20/200 or better
- NTG in both eyes with untreated IOP <21 mmHg at Visit 2 and morning assessment of Visit 3; IOP at morning assessment on Visits 2 and 3 doesn't differ more than 2 mmHg; has open iridocorneal angles, historic IOP <22 mmHg in either eye
Key exclusion criteria (11 listed)
- History of angle closure glaucoma, narrow or occludable angle on gonioscope
- All secondary glaucomas
- Severe glaucomatous damage that would preclude safe washout of prescribed ocular hypotensive medications
- Previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes, cyclodestructive procedure) (selective laser trabeculoplasty (SLT) allowed if done no earlier than 1 year from study, some minimally invasive glaucoma surgeries are allowed if done no earlier than 1.5 years from study)
- Ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis of eye
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QLS-111 ophthalmic solution (0.015%)Also: QLS-111QLS-111 ophthalmic solution 0.015% applied QPM OU for 7 days followed by BID dosing OU for 7 days, to constitute a 14-day study treatment period. All IP for this study will be supplied masked in PF single use vials. | Drug | QLS-111 ophthalmic solution |
| Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)Also: TimololTimolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) with BID dosing OU will be administered up to 14 days. All IP for this study will be supplied masked in PF single use vials. | Drug | Timolol maleate PF 0.5% Ophthalmic Solution |
Primary outcome
Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs)
Time frame: 14 days
Ocular safety and tolerability: (AEs)
Clinically significant change in visual acuity
Time frame: 14 days
Ocular safety and tolerability: visual acuity
Clinically significant change in findings on slit lamp exam
Time frame: 14 days
Ocular safety and tolerability: dilated biomicroscopy of eye to observe clinically significant changes from baseline
Clinically significant change in findings on fundus exam
Time frame: 14 days
Ocular safety and tolerability: dilated ophthalmoscopy to observe clinically significant changes from baseline in posterior segment of eye
Incidence of systemic TEAEs
Time frame: 14 days
Systemic safety and tolerability: AEs
Clinically significant changes in blood pressure (BP)
Time frame: 14 days
Systemic safety and tolerability: vital sign, measuring systolic and diastolic blood pressure
Clinically significant changes in heart rate (HR)
Time frame: 14 days
Systemic safety and tolerability: vital signs
2 secondary outcomes
Change from baseline (CFB) of diurnal intraocular pressure (IOP) in the study eye
Time frame: 14 days
CFB in IOP at various timepoints in the study eye
Time frame: 14 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2026.
- Company website, pipelineLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Normal Tension Glaucoma (NTG)
Not yet recruiting
DSLT in Normal Tension Glaucoma (NTG) Asian Eyes
Normal Tension Glaucoma (NTG), Glaucoma
Not yet recruitingObservational study
Optic Nerve Head Evaluation Through Multimodal Blood Flow Analysis: a Prospective Observational, Multi-center Study
Neuro-Ophthalmology, Optic Neuropathies
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lisa Brandano study director
Qlaris Bio, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing QLS-111 ophthalmic solution (0.015%) and Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) in people with Normal Tension Glaucoma (NTG) and Low-Tension Glaucoma, Bilateral, run by Qlaris Bio, Inc. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs) (time frame: 14 days). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2026; AzTrials last refreshed its copy on 7 Nov 2026.